Regulatory considerations for vaccine development, talk 2 clinical regulatory considerations (part 1 of 2) /

Regulatory considerations for vaccine development, talk 2 clinical regulatory considerations (part 1 of 2) /

Show other versions (2)
Saved in:
Bibliographic Details
Other Authors: Schrager, Lewis K. (Speaker)
Format: Electronic Video
Language:English
Published: London : Henry Stewart Talks, 2015.
Series:Henry Stewart talks. Biomedical & life sciences collection. Vaccines.
Subjects:
United States. > Food and Drug Administration.
Vaccines industry > Government policy > United States.
Vaccines > Development.
Clinical Trials as Topic > legislation & jurisprudence.
Drug Approval > methods.
Drug Industry > legislation & jurisprudence.
Investigational New Drug Application > legislation & jurisprudence.
Investigational New Drug Application > methods.
United States Food and Drug Administration > legislation & jurisprudence.
United States Food and Drug Administration > standards.
Vaccines > standards.
Online Access:https://hstalks.com/bs/3169/
Series
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000ngm a2200000 a 4500
001 HST4032
003 UkLoHST
006 m c
007 cr|cna|||a||||
007 vz|czazum
008 151211s2015 enk|||||||||||s|||v|eng d
028 5 0 |a 4032  |b Henry Stewart Talks 
035 |a (UkLoHST)3169 
040 |a UkLoHST  |b eng  |c UkLoHST 
100 1 |a Schrager, Lewis K.,  |u (Aeras, USA)  |4 spk  |9 100285 
245 1 0 |a Regulatory considerations for vaccine development, talk 2  |h [electronic resource] :  |b clinical regulatory considerations (part 1 of 2) /  |c Lewis K. Schrager. 
246 3 |a Clinical regulatory considerations. Part 1 
260 |a London :  |b Henry Stewart Talks,  |c 2015. 
300 |a 1 online resource (1 streaming video file (33 min.) :  |b color, sound). 
490 1 |a Vaccines : principles, recent developments and future directions,  |x 2056-452X 
500 |a Animated audio-visual presentation with synchronized narration. 
500 |a Title from title frames. 
505 0 |a Contents: Investigational New Drug (IND) regulations -- Key clinical development milestones -- Safety and efficacy concepts: a regulator's perspective. 
506 |a Access restricted to subscribers. 
538 |a Mode of access: World Wide Web. 
610 1 0 |a United States.  |b Food and Drug Administration.  |9 100286 
650 0 |a Vaccines industry  |x Government policy  |z United States.  |9 100287 
650 0 |a Vaccines  |x Development.  |9 100288 
650 2 |a Clinical Trials as Topic  |x legislation & jurisprudence.  |9 100289 
650 2 |a Drug Approval  |x methods.  |9 100290 
650 2 |a Drug Industry  |x legislation & jurisprudence.  |9 100291 
650 2 |a Investigational New Drug Application  |x legislation & jurisprudence.  |9 100292 
650 2 |a Investigational New Drug Application  |x methods.  |9 100293 
650 2 |a United States Food and Drug Administration  |x legislation & jurisprudence.  |9 100294 
650 2 |a United States Food and Drug Administration  |x standards.  |9 100295 
650 2 |a Vaccines  |x standards.  |9 100296 
830 0 |a Henry Stewart talks.  |p Biomedical & life sciences collection.  |p Vaccines.  |9 100297 
856 4 0 |u https://hstalks.com/bs/3169/ 
856 4 2 |u https://hstalks.com/bs/p/923/  |3 Series 
999 |c 214823  |d 214822 

Similar Items